Publicada en el Diario Vasco el 23-05-2023
Oncomatryx acquires Austrian company to consolidate its tumour microenvironment drugs
Basque Country Lehendakari´s visit
Iñigo Urkullu ha visitado la empresa biofarmacéutica Oncomatryx, desarrolladora de tratamientos personalizados para atacar los tumores invasivos Osakidetza, a través de Onkologikoa, formará parte de un ensayo clínico de cáncer con metástasis
Clinical Trial
Published by Deia 2022 – 05 -23
Oncomatryx Capital increase 2022
Published by EXPANSIÓN 2022-03-08 Oncomatryx has carried out a capital increase of 15 million euros to start clinical trials with people with invasive tumors in Spain and the USA.
Bizkaia Impacto Social 2022 Award
Published by El Correo 2022-03-07. Oncomatryx Biopharma, S.L. has been honoured with the 2022 Bizkaia Social Impact Award (Premio Impacto Social 2022) by BBK and EL CORREO at the Sustainable Competitiveness Awards
Capital Increase
Published by La Vanguardia 2015-12-15. Oncomatryx expands capital to complete the preclinical phase of drugs against tumor stroma The Basque company Oncomatryx has completed a round of capital increase of
DMTXinvaScan tested in US Hospitals
Press Release 2013-06-26 DMTXinvascan tested in US hospitals. Hospitals in the USA launch a Basque test to predict the metastasis of breast cancer Current diagnostic systems impede the detection in
New treatments against the most invasive cancer
Publisehed by El Dato Magazine el 2013-01-01 New treatments against the most invasive cancer Develops in collaboration with renowned public and private national and foreign companies, new drugs that help to